APA (7th ed.) Citation

V, F., MI, C., A, S., G, P., MC, A., A, E., . . . CA, L. (2026). Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. British journal of cancer, 134(11), 1671. https://doi.org/10.1038/s41416-026-03420-2

Chicago Style (17th ed.) Citation

V, Figueroa, et al. "Nuclear FGF2, Androgen Receptor and Wnt Pathway Activation Define a Targetable Subset of Antiprogestin-resistant Luminal Breast Cancer." British Journal of Cancer 134, no. 11 (2026): 1671. https://doi.org/10.1038/s41416-026-03420-2.

MLA (9th ed.) Citation

V, Figueroa, et al. "Nuclear FGF2, Androgen Receptor and Wnt Pathway Activation Define a Targetable Subset of Antiprogestin-resistant Luminal Breast Cancer." British Journal of Cancer, vol. 134, no. 11, 2026, p. 1671, https://doi.org/10.1038/s41416-026-03420-2.